Evaxion Biotech

Summary

History

Mission

Vision

References

Summary

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

History

Evaxion Biotech was founded in 2015 by scientists Sven Hanson and Jenny Nordvall. With the help of a team of experienced researchers, we have continued to investigate and develop innovative solutions for therapeutic treatments.

Mission

Our mission is to use our expertise to reduce the burden of disease on human and animal health and to improve the quality of life of our patients.

Vision

Our vision is to become the global leader in developing safe, innovative and effective therapeutic solutions for the medical challenges of our times.

References

https://in.investing.com/equities/evaxion-biotech-as-drc-o

https://finance.yahoo.com/quote/EVAX/profile?p=EVAX

https://www.crunchbase.com/organization/evaxion-biotech

https://www.evaxion-biotech.com

Leadership team

Dr. Niels Iversen Moeller M.D. (Co-Founder, VP of Bus. & Director)

Mr. Andreas Holm Mattsson (Co-Founder and Chief AI & Culture Officer)